(Q51772441)

English

[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.

scientific article published in May 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

author name string

Fabienne Iten

1

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Beat Muller

2

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Christian Schindler

3

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Helmut Rasch

4

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Christoph Rochlitz

5

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Daniel Oertli

6

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Helmut R Maecke

7

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

Jan Muller-Brand

8

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

language of work or name

0 references

publication date

1 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

115

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

10

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

2052-2062

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

New therapeutic approaches for metastatic thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Management of thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Combination therapy for anaplastic giant cell thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Phase II study of celecoxib in metastatic differentiated thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

21 January 2018

Papillary and follicular thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24272

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24272

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19280592

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51772441&oldid=2072797356"